The intradermal injection market is projected to reach US$ 7,415.70 million by 2028 from US$ 3,513.26 million in 2021 and is expected to register a CAGR of 11.3% from 2021 to 2028. The World Health Organization (WHO) recognizes waste reduction in healthcare delivery as an important aspect of strengthening health systems. Technological advancements have led to the development of surgical approaches that minimize waste and achieve better results with the available resources. The reusable intradermal devices are among the approaches that result in low waste generation, which has a net positive effect on the productivity of an economy. Along with this, the results of several meta-analyses also demonstrated that the intradermal delivery of drugs is able to reduce the intensity of adverse events, as a comparatively low concentration of the drug is required for achieving the optimum responses. The factors mentioned above indicate the favorable condition for the rapid growth of this segment in the future.